

Product Data Sheet

Product Name: M1069
Cat. No.: GC73150

Chemical Properties

Cas. No. 3027658-65-4


Formula $C_{25}H_{30}N_4O_8S$ M.Wt 546.59

Solubility DMSO : 100 mg/mL (182.95 mM; Need ultrasonic) Storage 4°C, sealed storage, away from moisture

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Background

M1069 is a selective and orally active, dual A_{2A}/A_{2B} adenosine receptor antagonist with a selectivity of >100 fold against the A₁ and A₃ receptors. M1069 counteracts immune-suppressive mechanisms

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

of adenosine, and exhibits anti-tumor activity.

Metabolically stressful conditions, including inflammation and cancer, induces extracellular concentrations of adenosine increase[1]. M1069 dose-dependently suppresses 5'-N-ethylcarboxamide adenosine (stable analog of adenosine)-stimulated cyclic adenosine monophosphate (cAMP) and phosphorylated cAMP- response element binding protein (pCREB) induction, inhibits interleukin (IL)-2 production[1]. M1069 suppresses vascular endothelial growth factor (VEGF) production from human macrophages in adenosine-rich settings[1]. M1069 inhibits protumorigenic cytokine secretion, such as CXCL1, CXCL5 and granulocyte-colony stimulating factor, and reduces IL-12 secretion from adenosine-differentiated dendritic cells[1]. M1069 enhances T-cells activation in adenosine-differentiated dendritic cells[1].

M1069 inhibits breast tumor (CD73hi/adenosine-rich 4T1 syngeneic) growth in vivo in mice and enhances chemotherapeutic agents efficacy[1].

References:

[1]. Rinat Zaynagetdinov, et al. Abstract 3499: M1069 as dual A2A/A2B adenosine receptor antagonist counteracts immune-suppressive mechanisms of adenosine and reduces tumor growth in vivo. *Cancer Res* (2022) 82 (12_Supplement):3499. [2]. Lillian L Siu, et al. Abstract CT240: A first-in-human study of the dual A2A/A2B adenosine receptor antagonist M1069 in patients with advanced solid tumors. *Cancer Res* (2022) 82 (12_Supplement):CT240. [3]. Tanzer Eva-Maria, et al. Preparation of thiazolopyridine derivatives as adenosine receptor antagonists: World Intellectual Property Organization, WO2020152132[P]. 2020-07-30.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA